Vanguard Group
ENVB icon

Vanguard Group’s Enveric Biosciences ENVB Stock Holding History

Vanguard Group’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-101
Closed -$6.51K – 4285
2024
Q4 		$6.51K Hold
101
– – ﹤0.01% 4287
2024
Q3 		$8.63K Hold
101
– – ﹤0.01% 4330
2024
Q2 		$11.4K Hold
101
– – ﹤0.01% 4386
2024
Q1 		$18.2K Hold
101
– – ﹤0.01% 4398
2023
Q4 		$23.7K Buy
101
+1
+1% +$307 ﹤0.01% 4431
2023
Q3 		$42.9K Buy
100
+30
+43% +$13.5K ﹤0.01% 4428
2023
Q2 		$42.2K Buy
70
+3
+4% +$1.46K ﹤0.01% 4477
2023
Q1 		$20.2K Sell
67
-13
-16% -$5.47K ﹤0.01% 4528
2022
Q4 		$30K Hold
80
– – ﹤0.01% 4477
2022
Q3 		$61K Sell
80
-5
-6% -$6.29K ﹤0.01% 4530
2022
Q2 		$163K Hold
85
– – ﹤0.01% 4491
2022
Q1 		$251K Hold
85
– – ﹤0.01% 4504
2021
Q4 		$707K Buy
85
+30
+55% +$422K ﹤0.01% 4358
2021
Q3 		$1.03M Buy
55
+35
+175% +$680K ﹤0.01% 4240
2021
Q2 		$432K Hold
20
– – ﹤0.01% 4293
2021
Q1 		$556K Buy
20
+19
+1,900% +$664K ﹤0.01% 4116
2020
Q4 		$52K Buy
+1
New +$52.5K ﹤0.01% 4179
2019
Q4 		– Hold
0
– -$31K – 4127
2019
Q3 		– Hold
0
– – – 4110
2019
Q2 		– Hold
0
– – – 4092
2019
Q1 		– Hold
0
– – – 4116

Other funds holding ENVB

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group's ENVB Position: Q1 2025 in Review

Vanguard Group sold out of Enveric Biosciences (ENVB) in Q1 2025, closing a stake of 101 shares — an estimated $6.51K sold.

Vanguard Group first reported a position in ENVB in Q4 2020 and held it in 17 quarters. The position peaked at $1.03M in Q3 2021. 13 funds tracked by Wall St. Rank hold ENVB as of Q1 2025.

  • Vanguard Group reported no remaining Enveric Biosciences position as of Q1 2025 after selling out during the quarter.
  • Vanguard Group sold 101 Enveric Biosciences shares in Q1 2025, an estimated $6.51K.
  • Vanguard Group first reported a position in Enveric Biosciences in Q4 2020 and held it in 17 quarters.
  • Vanguard Group's Enveric Biosciences position peaked at $1.03M in Q3 2021.
  • 13 funds tracked by Wall St. Rank held Enveric Biosciences as of Q1 2025.

Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.